March 7, 2018 / 10:38 PM / 5 months ago

BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima

March 7 (Reuters) - Eisai Co Ltd:

* EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE)

* MERCK & CO - CO, ‍​ISAI TO DEVELOP AND COMMERCIALIZE LENVIMA JOINTLY, BOTH AS MONOTHERAPY AND IN COMBINATION WITH MERCK’S ANTI-PD-1 THERAPY, KEYTRUDA

* MERCK & CO INC - GROSS PROFITS FROM LENVIMA PRODUCT SALES GLOBALLY WILL BE SHARED EQUALLY BY EISAI AND MERCK

* MERCK & CO - EXPENSES INCURRED DURING CO-DEVELOPMENT, INCLUDING FOR STUDIES EVALUATING LENVIMA AS MONOTHERAPY, TO BE SHARED EQUALLY BY CO, EISAI

* MERCK - TO PAY EISAI UPFRONT PAYMENT OF $300 MILLION U.S. DOLLARS AND UP TO $650 MILLION U.S. DOLLARS FOR CERTAIN OPTION RIGHTS THROUGH 2020 AS PER DEAL

* MERCK - TO ALSO PAY EISAI $450 MILLION AS REIMBURSEMENT FOR RESEARCH AND DEVELOPMENT EXPENSES AS PER DEAL

* MERCK & CO INC - EISAI IS ELIGIBLE TO RECEIVE MAXIMUM OF UP TO $3.97 BILLION FOR ACHIEVEMENT OF MILESTONES ASSOCIATED WITH SALES OF LENVIMA

* MERCK - AS PER DEAL, ‍EISAI IS ELIGIBLE TO RECEIVE UP TO $385 MILLION ASSOCIATED WITH ACHIEVEMENT OF CERTAIN CLINICAL AND REGULATORY MILESTONES​

* MERCK & CO - ASSUMING ACHIEVEMENT OF ALL GOALS FOR ALL INDICATIONS AS PER DEAL, TOTAL AMOUNT OF PAYMENTS TO EISAI COULD REACH UP TO $5.76 BILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below